Mergers & acquisitions
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, come into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
The planned acquisition will give Takeda full access to Adaptate’s antibody-based γδ T cell engager platform, which includes both pre-clinical and discovery assets.
Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
Absci Corporation inked a deal with Merck. Absci will leverage its Bionic Protein non-standard amino acid technology and AI-integrated Drug Creation Platform to create enzymes for Merck.
PRESS RELEASES